
- | Portage Biotech
Portage Biotech (PRTG) CEO With A Company Overview
Portage Biotech (PRTG) researches and develops pharmaceutical and biotechnology products. Dr. Ian Walters, CEO of Portage Biotech, gives an overview of the company and the outlook for Portage Biotech. Portage Biotech partners with immune-oncology companies to guide novel cancer treatments through clinical development. Tune in to find out more.

- | Selecta Biosciences
Has Selecta found a way around gene therapy’s delivery problem? Takeda puts down $1B-plus to find out
Selecta’s platform makes use of a biodegradable nanoparticle that encapsulates the immunosuppressive drug rapamycin, and is designed to be given in conjunction with gene therapies to induce antigen-specific immune tolerance.

- | Cerevance
Question: In Fintech, How Much Is Too Much for Investors?
Brad Margus, chief executive of drug-discovery company Cerevance, said that lowering drug prices will especially hurt companies working on the hardest-to-crack diseases, where even though a drug that works would have a huge market, it’s nearly impossible to persuade investors to support new approaches. “The price controls now being pushed threaten to remove the chance for my investors to get those returns,” he said.

- | Celyad Oncology
Novel CAR T Therapies Help Celyad’s CMO Bring Hope to Fearful Patients
Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies. “Approved cell therapy products have a very, very high response rate,” he said. “The challenge is in expanding that therapy from hematologic malignancies to other targets – in particular, to solid tumors – where we, as a field, haven’t yet cracked the code.”

- | TFF Pharmaceuticals
Austin-based company developing treatment for lung transplant recipients, COVID survivors
Dale Christensen is the Director of Clinical Development at TFF Pharmaceuticals. It’s an Austin-based company and specializes in “Thin Film Freezing”—a technology first created at UT Austin.

- | Elicio Therapeutic
Lymph node-targeted vaccine elicits COVID-19 protection in vivo
Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity to SARS-CoV-2 in a pre-clinical study.

- | Scynexis
Scynexis debuts Brexafemme
Scynexis is introducing Brexafemme (ibrexafungerp tablets), the first and only oral non-azole prescription medication approved by the Food and Drug Administration to treat vulvovaginal candidiasis, commonly referred to as vaginal yeast infection.

- | DURECT
PharmaShots Interview: Durect’s James E. Brown Shares Insight on the Data of DUR-928 Presented at EASL 2021
In an interview with PharmaShots, James E. Brown, President, CEO, and Director of Durect shared his views on the clinical data of DUR-928 in P-1b trial for NASH and P-I trial for Hepatic Impairment